Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis

Hannaford, A., Byth, K., Pavey, N., Henderson, R.D., Mathers, S., Needham, M., Schultz, D., Menon, P., Kiernan, M.C. and Vucic, S. (2022) Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis. Muscle & Nerve . Early View.

Link to Published Version: https://doi.org/10.1002/mus.27736
*Subscription may be required

Abstract

Introduction/Aims

Rate of disease progression (ΔFS), measured as change in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and body mass index (BMI), are predictors of survival in amyotrophic lateral sclerosis (ALS). Our aim in this study was to assess the utility of these clinical biomarkers along with neurophysiological measures, such as the split hand index (SI), in monitoring disease progression.

Methods

Clinical trial data were collected from 107 patients recruited into the Tecfidera in ALS trial. The prognostic utility of clinical and neurophysiological measures, including ΔFS, BMI, SI, and neurophysiological index (NPI), were assessed cross-sectionally and longitudinally (40 weeks). The outcome measures of disease severity and progression included: (i) ALSFRS-R score; (ii) Medical Research Council (MRC) score; and (iii) forced vital capacity and sniff nasal inspiratory pressure.

Results

Fast-progressor ALS patients (ΔFS ≥1.1) exhibited significantly lower ALSFRS-R and total MRC scores at baseline. A baseline ΔFS score ≥1.1 was associated with a greater reduction in ALSFRS-R (P = .002) and MRC (P = .002) scores over 40 weeks. Baseline BMI <25 was also associated with faster reduction of ALSFRS-R and MRC scores. SI and NPI were associated with disease severity at baseline, but not with subsequent rate of disease progression.

Discussion

Implementation of the assessed clinical and neurophysiological biomarkers may assist in patient management and stratification into clinical trials.

Item Type: Journal Article
Murdoch Affiliation(s): Centre for Molecular Medicine and Innovative Therapeutics
Publisher: John Wiley and Sons Inc.
Copyright: © 2022 Wiley Periodicals LLC.
URI: http://researchrepository.murdoch.edu.au/id/eprint/66503
Item Control Page Item Control Page